Fortrea Holdings Inc. Q3 FY2026 earnings call

Commercial Excellence:

• Fortria is executing a return-to-growth strategy focused on revenue growth and margin expansion through commercial, operational, and financial excellence pillars.
• The company has enhanced its commercial capabilities via talent acquisition, analytical tools, and integrated account management, allowing for flexible service models (FSO, FSP, and point solutions).
• A new leader was appointed in China to drive growth with both China-headquartered biotechs and multinational sponsors, leveraging China's role as a key source of global drug development innovation.
• The go-to-market model emphasizes 'Reach' (expanding customer relationships), 'Relevance' (early integration of expertise), and 'Repeat' (delivering consistent client experiences).

Operational Excellence:

• Consistency in delivery remains paramount, with focus areas including project management, site activation, enrollment, quality, and predictability.
• Clinical pharmacology services are a differentiated area benefiting from strong scientific capabilities and faster revenue conversion rates.
• Fortria completed the acquisition of the early-phase services business from Worldwide Clinical Trials, expanding US and UK bed capacity to over 570 and adding bioanalytical and safety lab capabilities.
• New facilities in San Antonio and Austin, Texas, create a 300-bed network enabling larger bioequivalence studies and in-house testing, reducing reliance on third parties.
• Technology initiatives include the launch of 'Fortrea Intelligent Technology' (FIT), which integrates AI, machine learning, and risk intelligence into workflows.
• The internal 'Felix' program has achieved high AI literacy adoption, with over 95% of colleagues integrating AI into weekly routines.

Financial Excellence:

• Major cost structure alignment actions are largely complete, shifting focus toward sustainable growth and margin expansion.
• Management expects margin expansion to be driven by revenue growth, favorable business mix, improved utilization, and operating leverage.
• The goal is to reach mid-teens adjusted EBITDA margins through profitable growth rather than growth at any cost.
• Capital allocation priorities include investing in organic growth, productivity improvements, and targeted acquisitions that meet disciplined return thresholds.

Fortria reported total revenue of $691.5 million for the third quarter of 2026, representing a 1.4% decrease year-over-year and a 2.0% increase sequentially. The company did not break down specific financial performance percentages by product segment in the provided text; however, it highlighted that revenue conversion from backlog accelerated by 30 basis points compared to the previous quarter, driven primarily by the Fixed Service Organization (FSO) and Fixed Service Plan (FSP) portfolios. Adjusted EBITDA was $58.0 million, with an adjusted EBITDA margin of 8.4%, reflecting a 120 basis point expansion year-over-year.

• Full-year 2026 Revenue Guidance: Raised midpoint and narrowed range; now expected to be between $2.665 billion and $2.690 billion.
• Full-year 2026 Adjusted EBITDA Guidance: Raised midpoint and narrowed range; now expected to be between $210 million and $218 million.
• Free Cash Flow: Management continues to expect positive free cash flow in the fourth quarter and for the full year 2026.
• 2027 Outlook: No specific numerical guidance provided for 2027; management emphasized the importance of consistent bookings and market recovery signals to determine future growth trajectory.

• Backlog Adjustment: A cumulative adjustment of $558 million was recorded to backlog to better reflect remaining revenue expectations, inclusive of inactive trials and scope changes. While this does not impact reported financial results or near-term revenue planning, it indicates ambiguity in contract statuses and potential long-term revenue bleed-off.
• Market Recovery Uncertainty: Although the market is showing signs of recovery, particularly in biotech, progress depends on sustained demand from large pharma and biotech sectors.
• Operational Execution Risks: Consistency in clinical trial execution, site activation, and enrollment remains critical; failures in these areas could impact margins and repeat business.
• Integration Risks: The recent acquisition of Worldwide Clinical Trials’ early-phase services introduces integration challenges, particularly regarding commercial conversion and embedding the business into existing pipelines.
• Geopolitical Factors: Potential impacts from geopolitical tensions, such as the COIN Act proposal, could affect operations in China, though current management sees no immediate negative impact on service provision.

Q: Analyst asked about factors impacting Q4 guidance and TSA dynamics post-acquisition. / A: CFO explained Q4 guidance reflects fewer working days vs Q3 and slight IT OpEx increases. Regarding the TSA, support functions are covered, but commercial conversion takes time as pre-acquisition collaboration already began.

Q: Analyst sought details on the $558M backlog adjustment, asking if it included inactive trials and non-deliverables. / A: CFO clarified the adjustment ensures backlog reflects remaining life revenue, comprising inactive studies and 'not to deliver' dynamics due to sponsor reprioritization. He noted this does not impact near/medium-term revenue modeling or variables.

Q: Analyst asked about gross margin drivers and if Q4 burn rate implies ~8.5% for 2027. / A: CFO attributed margin improvement to favorable portfolio mix and operational efficiencies, offset by compensation investments. He confirmed Q4 burn rate assumptions align with working day dynamics and improving conversion rates.

Q: Analyst requested context on demand by customer cohort (biotech vs. biopharma) and segment. / A: CEO stated the sector is mid-recovery; biotech recovered faster with double-digit booking growth, while biopharma is now generating significant RFP flow. Both segments show healthy pipeline activity.

Q: Analyst asked if large pharma wallet share is changing and if scale matters more for winning work. / A: CEO noted increased RFP inflows from biopharma, including new outsourcing models where Fortria recently won work. He affirmed that scale remains critical for biopharma clients, who view top-tier CROs as viable partners.